Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 56 of 530 for:    VANCOMYCIN

A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population (EXTEND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02254967
Recruitment Status : Completed
First Posted : October 2, 2014
Last Update Posted : November 14, 2018
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe Ltd. )

Brief Summary:
The main objective of the study is to evaluate whether the extended duration fidaxomicin therapy is superior to the standard vancomycin therapy in sustained clinical cure of CDI at 30 days after end of treatment (Day 40 or Day 55).

Condition or disease Intervention/treatment Phase
Clostridium Difficile Drug: Fidaxomicin Drug: Vancomycin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 364 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIIB/IV Randomized, Controlled, Open-label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium Difficile Infection in an Older Population
Actual Study Start Date : November 6, 2014
Actual Primary Completion Date : March 27, 2016
Actual Study Completion Date : May 5, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Fidaxomicin Extended Pulsed Regimen (EPFX)
Participants receive 200 mg fidaxomicin from day 1 to day 5 twice daily, followed by a 1-day gap (day 6) before starting alternate day dosing of 1 tablet of fidaxomicin 200 mg once daily from day 7 to day 25.
Drug: Fidaxomicin
oral tablets administered in an extended pulsed regimen
Other Names:
  • OPT-80
  • ASP2819
  • Dificlir
  • Dificid

Experimental: Vancomycin
Participants receive 125 mg vancomycin from day 1 to day 10, 4 times daily.
Drug: Vancomycin
oral capsule
Other Name: Vancocin




Primary Outcome Measures :
  1. Percentage of Participants with a Sustained Clinical Cure of CDI at 30 Days after End of Treatment [ Time Frame: Day 40 (for vancomycin) and day 55 (for fidaxomicin extended pulsed regimen [EPFX]) ]
    Sustained clinical cure is defined as an assessment of clinical response at test of cure (TOC; day 12 for vancomycin and day 27 or 12 for EPFX arm) and no recurrence of CDI from TOC until time of assessment. Clinical response is determined by the investigator based on the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) criteria at TOC. Treatment response is present when either stool frequency decreases or stool consistency improves and parameters of disease severity (clinical, laboratory, radiological) improves and no new signs of severe disease develops.


Secondary Outcome Measures :
  1. Percentage of Participants with a Sustained Clinical Cure of CDI at Day 40, Day 55 and Day 90 [ Time Frame: Day 40, 55, 90 ]
    Sustained clinical cure is defined as an assessment of clinical response at test of cure (TOC; day 12 for vancomycin and day 27 or 12 for EPFX arm) and no recurrence of CDI from TOC until time of assessment. Clinical response is determined by the investigator based on the ESCMID criteria at TOC. Treatment response is present when either stool frequency decreases or stool consistency improves and parameters of disease severity (clinical, laboratory, radiological) improves and no new signs of severe disease develops.

  2. Percentage of Participants with a Clinical Response of CDI at 2 Days after End of Treatment [ Time Frame: Day 12, 27 ]
    Clinical response is determined by the investigator based on the ESCMID criteria (i.e., Treatment response is present when either stool frequency decreases or stool consistency improves and parameters of disease severity [clinical, laboratory, radiological] improves and no new signs of severe disease develops. Treatment response should be daily observed and evaluated after at least three days, assuming that the patient is not worsening on treatment) at TOC.

  3. Percentage of Participants with a Clinical Response of CDI at Day 12 [ Time Frame: Day 12 ]
    Clinical response is determined by the investigator based on the ESCMID criteria (i.e., Treatment response is present when either stool frequency decreases or stool consistency improves and parameters of disease severity [clinical, laboratory, radiological] improves and no new signs of severe disease develops. Treatment response should be daily observed and evaluated after at least three days, assuming that the participant is not worsening on treatment) at TOC.

  4. Number of Participants with a Relapse on Day 90 as Determined by Whole Genome Sequencing of C. Difficile Isolates [ Time Frame: Baseline through day 90 ]
    For participants with a recurrence after TOC, whole genome sequencing of isolates is performed on paired samples from day 1 and the day of the confirmed recurrence. Relapse is defined as paired isolates from a single recurrent participant with ≤ 2 single nucleotide variations (SNVs).

  5. Time to Resolution of Diarrhea (TTROD) [ Time Frame: Up to day 10 (for vancomycin) or up to day 25 (for EPFX) ]
    Time to resolution of diarrhea is defined as the time elapsing (in hours rounded up from minutes > 30) from the start of treatment (time of first dose of study drug) to resolution of diarrhea (time of the last unformed bowel movement [UBM] the day prior to the first of 2 consecutive days of ≤ 3 UBMs, > 50% reduction in number of stools or > 75% reduction in volume of liquid stool) that are sustained through to TOC.

  6. Percentage of Participants with a Recurrence of CDI at Day 40, Day 55 and Day 90 [ Time Frame: Day 40, 55, 90 ]
    For participants with clinical response at TOC, recurrence of CDI is defined as re-establishment of diarrhea after TOC to an extent (judged by the frequency of passed UBMs) that is greater than the frequency recorded on day 10 for vancomycin arm or day 25 for EPFX arm (2 days prior to TOC), confirmed by a CDI test positive for Toxin A/B and requiring further CDI therapy.

  7. Time to Recurrence of CDI after End of Active Treatment [ Time Frame: From day 10 up to day 90 ]
    Time to recurrence of CDI is defined as the time in days from clinical response until onset of recurrence of CDI for participants who respond at TOC.

  8. Disease-free Survival After Day 10 [ Time Frame: From day 10 up to day 90 ]
    Disease-free survival is defined as the time in days a participant does not have symptoms of diarrhea from day 10 up to day 90 for participants who respond at TOC.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • CDI is confirmed by clinical symptoms (either > 3 unformed bowel movements or ≥ 200ml of unformed stool (for subjects having rectal collection devices)) in the 24 hours prior to randomization and CDI test confirmed positive for presence of C. difficile toxin A or B in stool within 48 hr prior to randomization.
  • Subject agrees not to participate in another interventional study whilst participating in this study.

Exclusion Criteria:

  • Subject is taking or requiring to be treated with prohibited medications
  • Subject has received more than one day of dosing of any therapy for CDI within the last 48 hours
  • Subject has experienced more than 2 previous episodes of CDI in the 3 months prior to study enrolment
  • Subject is unable to swallow oral study medication.
  • Subject has a current diagnosis of toxic megacolon.
  • Subject is not willing to adhere to the provisions of treatment and observation specified in the protocol.
  • Subject has been randomized into this study previously, has taken any investigational drug within 28 days or 5 half lives, whichever is longer, prior to enrollment, or is currently participating in another clinical study which may influence the assessment of efficacy and/or safety endpoints of this study, in the opinion of the Sponsor.
  • Subject has previously participated in a CDI vaccine study
  • Subject has hypersensitivity to fidaxomicin, vancomycin or any of its components.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02254967


  Show 109 Study Locations
Sponsors and Collaborators
Astellas Pharma Europe Ltd.
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Director: Medical Director Astellas Pharma Europe Ltd.

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Astellas Pharma Europe Ltd.
ClinicalTrials.gov Identifier: NCT02254967     History of Changes
Other Study ID Numbers: 2819-MA-1002
2013-004619-31 ( EudraCT Number )
First Posted: October 2, 2014    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access Criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
URL: https://www.clinicalstudydatarequest.com/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Europe Ltd. ):
Aged
Fidaxomicin
Clostridium Difficile
Vancomycin
Additional relevant MeSH terms:
Layout table for MeSH terms
Clostridium Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Vancomycin
Fidaxomicin
Anti-Bacterial Agents
Anti-Infective Agents